Proton Beam Radiotherapy Versus Three-Dimensional Conformal Stereotactic Body Radiotherapy in Primary Peripheral, Early-Stage Non-Small-Cell Lung Carcinoma: A Comparative Dosimetric Analysis

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 950-958

  Macdonald, O Kenneth ^a   Kruse, Jon J ^a   Miller, Janelle M ^a   Garces, Yolanda I ^a   Brown, Paul D ^a   Miller, Robert C ^a   Foote, Robert L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Lung cancer; Proton therapy; Stereotactic body radiotherapy

Indexed keywords

LUNG CANCER; LUNG CARCINOMA; NON SMALL CELL LUNG CANCER; NORMAL TISSUE; ORGANS AT RISKS; PLANNING TARGET VOLUMES; PROTON BEAM RADIOTHERAPY; PROTON RADIOTHERAPY; PROTON THERAPY; SOFT TISSUE; STEREOTACTIC BODY RADIOTHERAPY; TREATMENT PLANS;

ABERRATIONS; CELL MEMBRANES; DOSIMETERS; DOSIMETRY; HISTOLOGY; PHOTOTRANSISTORS; PROTON BEAMS; PROTONS; RADIOTHERAPY; SKIN;

BIOLOGICAL ORGANS;

ARTICLE; CANCER CONTROL; CONTROLLED STUDY; DOSIMETRY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; PRIORITY JOURNAL; PROTON RADIATION; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROTONS; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; RIBS; SKIN; TUMOR BURDEN;

EID: 70349554150     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.023     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Mountain C.F. A new international staging system for lung cancer. Chest 89 (1986) 225S-233S
3. Naruke T., Goya T., Tsuchiya R., et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96 (1988) 440-447
4. Baumann P., Nyman J., Lax I., et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45 (2006) 787-795
5. Fritz P., Kraus H.J., Muhlnickel W., et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 1 (2006) 30
6. Onimaru R., Shirato H., Shimizu S., et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56 (2003) 126-135
7. Onishi H., Shirato H., Nagata Y., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2 (2007) S94-S100
8. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24 (2006) 4833-4839
9. Wulf J., Haedinger U., Oppitz U., et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: A noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60 (2004) 186-196
10. Xia T., Li H., Sun Q., et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66 (2006) 117-125
11. Glimelius B., Ask A., Bjelkengren G., et al. Number of patients potentially eligible for proton therapy. Acta Oncol 44 (2005) 836-849
12. Goitein M., and Cox J.D. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol 26 (2008) 175-176
13. Lee C.H., Tait D., Nahum A.E., et al. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol 72 (1999) 1078-1084
14. Lomax A. Intensity modulation methods for proton radiotherapy. Phys Med Biol 44 (1999) 185-205
15. Chang J.Y., Zhang X., Wang X., et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1087-1096
16. Georg D., Hillbrand M., Stock M., et al. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol 88 (2008) 368-375
17. Zhang X., Zhao K.L., Guerrero T.M., et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72 (2008) 278-287
18. Hernando M.L., Marks L.B., Bentel G.C., et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 650-659
19. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
20. Wang S., Liao Z., Wei X., et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66 (2006) 1399-1407
21. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54 (2002) 329-339
22. Dunlap N.E., Biedermann G.B., Yang W., et al. Chest wall volume receiving more than 30 Gy predicts risk of severe pain and/or rib fracture following lung SBRT. [Abstract]. Int J Radiat Oncol Biol Phys 72 Suppl. 1 (2008) S36
23. Voroney J.P.J., Hope A., Dahele M.R., et al. Pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. [Abstract]. Int J Radiat Oncol Biol Phys 72 Suppl. 1 (2008) S35
24. Hoppe B.S., Laser B., Kowalski A.V., et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: Who's at risk?. Int J Radiat Oncol Biol Phys 72 (2008) 1283-1286
25. Hall E.J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65 (2006) 1-7
26. Mesoloras G., Sandison G.A., Stewart R.D., et al. Neutron scattered dose equivalent to a fetus from proton radiotherapy of the mother. Med Phys 33 (2006) 2479-2490
27. Wroe A., Rosenfeld A., and Schulte R. Out-of-field dose equivalents delivered by proton therapy of prostate cancer. Med Phys 34 (2007) 3449-3456
28. Zacharatou Jarlskog C., Lee C., Bolch W.E., et al. Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms. Phys Med Biol 53 (2008) 693-717
29. Paganetti H., Jiang H., and Trofimov A. 4D Monte Carlo simulation of proton beam scanning: Modelling of variations in time and space to study the interplay between scanning pattern and time-dependent patient geometry. Phys Med Biol 50 (2005) 983-990
30. Grozinger S.O., Bert C., Haberer T., et al. Motion compensation with a scanned ion beam: A technical feasibility study. Radiat Oncol 3 (2008) 34